Crede Ecto Tracypor may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Amitraz is reported as an ingredient of Crede Ecto Tracypor in the following countries:
Cypermethrin is reported as an ingredient of Crede Ecto Tracypor in the following countries:
International Drug Name Search
Iodovine may be available in the countries listed below.
Povidone-Iodine is reported as an ingredient of Iodovine in the following countries:
International Drug Name Search
In the US, Zemaira (alpha 1-proteinase inhibitor systemic) is a member of the drug class miscellaneous respiratory agents and is used to treat Alpha-1 Proteinase Inhibitor Deficiency.
US matches:
Alpha1-protease inhibitor is reported as an ingredient of Zemaira in the following countries:
International Drug Name Search
Collu-Hextril may be available in the countries listed below.
Hexetidine is reported as an ingredient of Collu-Hextril in the following countries:
International Drug Name Search
Generic Name: Reteplase
Class: Thrombolytic Agents
Chemical Name: 173-l-Serine-174-l-lysine-175-l-glutamine-173-527-plasminogen activator (human tissue-type)
Molecular Formula: C1736H2653N499O522S22
CAS Number: 133652-38-7
Thrombolytic agent; biosynthetic (recombinant DNA origin) form of human tissue-type plasminogen activator (t-PA).1
Management of selected cases of acute evolving transmural MI in conjunction with heparin and/or platelet-aggregation inhibitors (i.e., aspirin).1 2 3 4 7 15 16 Lysis of coronary artery thrombi associated with acute evolving transmural MI1 15 16 and the resulting reperfusion can improve ventricular function and reduce the incidence of CHF, cardiogenic shock, and associated post-MI mortality.1 2 3 7 8 16
Clinical benefit diminishes as the time period from symptom onset to initiation of therapy increases.2 3 5 6 15 16 19 If possible, administer thrombolytic therapy within 30 minutes of hospital admission or first contact with the health-care system.15 16 19
The American College of Chest Physicians (ACCP), AHA, and ACC recommend use of any approved thrombolytic agent (e.g., alteplase, reteplase, tenecteplase, streptokinase [no longer commercially available in the US]) in patients having ischemic symptoms for ≤12 hours and ST-segment elevation or new or presumed new left bundle-branch block, unless contraindications exist.15 16 19 ACCP states that reteplase may be used in patients with acute MI who can be treated within 6 hours of symptom onset; however, alteplase or tenecteplase is recommended.16
ACCP suggests thrombolytic therapy in high-risk patients with ischemic symptoms characteristic of an acute MI or hemodynamic compromise present for 12–24 hours who have persistent ST-segment elevation or left bundle-branch block with concomitant ST-segment elevation changes if primary PCI is not readily available.16 ACC and AHA state that thrombolytic therapy is reasonable within 12–24 hours of symptom onset in patients with persistent ischemic symptoms accompanied by ST-segment elevation, provided no contraindications exist.15 19
Thrombolytic therapy may be reasonable in patients with true posterior MI presenting within 12 hours after onset of symptoms.15 16 19
Thrombolytic therapy suggested by ACCP in patients with acute massive embolism† accompanied by unstable hemodynamics who are not at risk for hemorrhage.17 However, ACCP states that use of thrombolytic therapy for treatment of PE remains controversial because of the lack of studies supporting this use and the high risk of bleeding.20 (See Effects on Hemostasis under Cautions.)
Generally reserve IV thrombolytic therapy for those with PE accompanied by unstable hemodynamics (e.g., shock) who do not have major contraindications because of bleeding risk20 or those with stable hemodynamics with other poor prognostic factors (e.g., marked dyspnea, anxiety and low oxygen saturation; elevated troponin concentrations indicating right ventricular microinfarction; echocardiographic evidence of right ventricular dysfunction, right ventricular enlargement on a chest computed-tomography scan).20
Perform a rapid risk assessment to determine if thrombolytic therapy is appropriate; irreversible cardiogenic shock may occur if therapy is delayed in patients with evidence of hemodynamic compromise.20
Institute therapy as soon as possible after acute MI.1 3 4 5 6 15 16 (See Acute MI under Uses.)
For drug compatibility information, see Drug Compatibility under Stability.
Administer IV.1
Do not add other IV substances, additives, or other drugs to reteplase solution and do not infuse anything else simultaneously through the same IV line.1
If administered via an IV administration set that is used for infusing heparin, flush line with 0.9% sodium chloride or 5% dextrose solution prior to and following drug administration.1
Reconstitute with 10 mL of sterile water for injection without preservatives to provide a solution containing 1 unit/mL.1 Use dispensing pin and diluent provided by the manufacturer.1 12
If foaming (usually slight) occurs, leave the vial undisturbed for several minutes.1 Gently swirl until the contents are completely dissolved; avoid shaking.1
Administer over 2 minutes.1
Expressed in reteplase-specific units, but also may be expressed in mg; each reteplase-specific unit is equivalent to 1.74 mg.1
Total dose is 20 units, given as two 10-unit IV injections 30 minutes apart.1
Lower doses of reteplase (two 5-unit doses 30 minutes apart) have been used in conjunction with a platelet glycoprotein (GP IIb/IIIa)-receptor inhibitor, heparin, and aspirin.13 14 15 16 (See Interactions.)
ACCP suggests a total dose of 20 units, given as two 10-unit IV injections 30 minutes apart.17
Active internal bleeding.1 3 9 15 19
History of cerebrovascular accident.1 8 15 16
Recent intracranial or intraspinal surgery or trauma.1 9 15 16
Intracranial neoplasm.1 7 15 19
Intracranial vascular disease (i.e., arteriovenous malformation, aneurysm).1 7 15 19
Known bleeding diathesis.1 7 15 19
Severe uncontrolled hypertension.1 6 7 9 11 15
History of intracranial hemorrhage.15 16 19
Suspected aortic dissection.15 19
Recent (within 3 months) facial trauma.15 19
Possible bleeding, including internal bleeding at intracranial or retroperitoneal sites or bleeding from the GI, GU, or respiratory tract.1 Superficial or surface bleeding at vascular puncture and access sites (e.g., venous cutdowns, arterial punctures) or sites of recent surgical intervention also may occur.1
Weigh increased risks of therapy against anticipated benefits in patients with recent major surgery (e.g., CABG), obstetric delivery, organ biopsy, previous puncture of noncompressible vessels, cerebrovascular disease, hypertension (SBP ≥180 mm Hg and/or DBP ≥110 mm Hg), hemostatic defects (e.g., secondary to severe hepatic or renal disease), recent GI (e.g., active peptic ulcer) or GU bleeding, or recent trauma.1 15 Also, weigh risks against benefits of therapy in patients with diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions.1 Weigh risks against benefits in patients receiving concurrent oral anticoagulant therapy (e.g., warfarin).1 15 Weigh risks against benefits in patients with any condition in which bleeding constitutes a substantial hazard or would be particularly difficult to manage because of its location.1
Initiate therapy only after careful screening for contraindications.1
Minimize risk of bleeding by carefully selecting patients and monitoring all potential bleeding sites (e.g., sites of all venous cutdowns, arterial and venous punctures, needle punctures).1 Avoid IM injections and nonessential handling of patient.1 Perform invasive venous procedures carefully and as infrequently as possible.1 Minimize arterial punctures.1 Avoid arterial and venous invasive procedures in areas that are inaccessible to manual compression (e.g., internal jugular or subclavian punctures).1 Use of an artery in an upper extremity is preferred if an arterial puncture is essential.1 Apply pressure to the puncture site for ≥30 minutes followed by a pressure dressing and frequent inspection of the puncture site for bleeding.1
If serious bleeding occurs, immediately discontinue anticoagulant therapy; heparin anticoagulation can be reversed with protamine sulfate.1 Do not administer a second injection of reteplase if serious bleeding occurs with the first injection.1
Possible fatal cardiogenic shock, heart failure, cardiac arrest, recurrent myocardial ischemia or infarction, myocardial rupture, AV block, electromechanical dissociation, pericardial effusion, pericarditis, mitral regurgitation, cardiac tamponade, hypotension, pulmonary edema, or thromboembolism.1
Weigh risks against anticipated benefits of therapy in patients with a high likelihood of left heart thrombus (e.g., mitral stenosis with atrial fibrillation), acute pericarditis, subacute bacterial endocarditis, septic thrombophlebitis, or an occluded arteriovenous cannula at a seriously infected site.1
Possibly fatal cholesterol crystal embolization associated with invasive vascular procedures (e.g., cardiac catheterization, angiography, vascular surgery) and/or thrombolytic agents.1 Clinical features of cholesterol embolism include livedo reticularis, “purple toe” syndrome, acute renal failure, gangrenous digits, hypertension, pancreatitis, MI, cerebral infarction, spinal cord infarction, retinal artery occlusion, bowel infarction, and rhabdomyolysis.1
Possible reperfusion-related arrhythmias (e.g., sinus bradycardia, accelerated idioventricular rhythm, VPCs, VT).1 6 10 11
Have appropriate antiarrhythmic therapy available during and after administration.1 6
Allergic-type (e.g., pruritus, rash, urticaria) or anaphylactoid reactions (e.g., dyspnea, hypotension) reported rarely.1 7 13
Institute appropriate therapy if an anaphylactoid reaction occurs.1
Repeat courses not systematically studied.1 Do not administer second dose if anaphylaxis occurs with first dose.1
Category C.1
Increases risk of therapy in pregnant women; weigh risks against benefits of therapy in pregnant women.1
Not known whether reteplase is distributed into milk.1 Caution if used in nursing women.1
Safety and efficacy not established in children <18 years of age.1 13
Intracranial hemorrhage more common.1 4 5 6 Weigh risks of drug against potential benefits.1
Weigh the risks of therapy against the potential benefits in patients with severe hepatic impairment.1
Weigh the risks of therapy against the potential benefits in patients with severe renal impairment.1
Bleeding.1
Drug | Interaction | Comments |
|---|---|---|
Abciximab | Increased risk of hemorrhage1 14 15 16 | Concomitant use not recommended by some clinicians16 Use suggested by other clinicians in selected patients with no risk factors for bleeding15 |
Aspirin | Increased risk of hemorrhage1 14 15 16 | Monitor carefully for bleeding, especially at arterial puncture sites1 |
Dipyridamole | Increased risk of hemorrhage1 14 15 16 | |
Heparin | Increased risk of hemorrhage1 14 15 16 | Monitor carefully for bleeding, especially at arterial puncture sites1 |
Warfarin | Increased risk of hemorrhage1 15 16 | Weigh risks against anticipated benefits1 |
Not known whether reteplase is distributed into human milk.1
Cleared by the liver and kidney.1
13–16 minutes.1
2–25°C; protect from light.1
Reconstituted solutions contain no preservative.1 Preferably use solution immediately after preparation; may be used up to 4 hours after reconstitution if stored at 2–30°C.1 Discard any unused solution after 4 hours.1
For information on systemic interactions resulting from concomitant use, see Interactions.
Reteplase is incompatible with heparin.1
Incompatible |
|---|
Bivalirudin |
Binds to fibrin and converts plasminogen to plasmin.1 Plasmin degrades the fibrin matrix of the thrombus.1
Decreased fibrin affinity compared with alteplase.2 3 4 7 8 10
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses or recent surgery.1
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1 6
Importance of informing patients of other important precautionary information.1 (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Parenteral | For IV use only | 10.4 units (18.1 mg) | Retavase (with reconstitution kit containing sterile water for injection diluent and a double-ended sterile dispensing pin) | PDL BioPharma |
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions February 2011. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
1. PDL BioPharma, Inc. Retavase (reteplase, recombinant) injection prescribing information. Freemont, CA; 2006 Jan.
2. Topol EJ, Ohman M, Armstrong PW et al. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III trial. Circulation. 2000; 102:1761-5. [IDIS 454027] [PubMed 11023929]
3. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997; 337:118-23.
4. Cairns JA, Kenedy JW, Fuster V. Coronary thrombolysis. Chest. 1998; 114:(Suppl 5S):634-57S.
5. Ryan TJ, Antman EM, Brooks NH et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: 1999 update: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1999; 34:89-911.
6. Internation Liason Committee on Resuscitation. Guidelines 2000 for cardiopulmonary rsuscitation and emergency cardiovascular care: an international consensus on science. Part 7, section 1. Acute coronary syndromes (acute myocardial infarction). Circulation. 2000; 102(Suppl. I):I-172-203.
7. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet. 1995; 346:329-36. [IDIS 351255] [PubMed 7623530]
8. Smalling RW, Bode C, Kalbfleisch J et al et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation. 1995; 91:2725-32. [IDIS 348924] [PubMed 7758177]
9. Bode C, Smalling RW, Berg G et al et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation. 1996; 94:891-8. [IDIS 372165] [PubMed 8790022]
10. Tebbe U, von Essen R, Smolarz A et al. Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction. Am J Cardiol. 1993; 72:518-24. [IDIS 319465] [PubMed 8362764]
11. Neuhaus KL, von Essen R, Vogt A et al. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German recombinant plasminogen activator study. J Am Coll Cardiol. 1994; 24:55-60. [IDIS 332009] [PubMed 8006283]
12. Boehringer Mannheim Corporation, Gaithersburg, MD: Personal communication.
13. Centocor Inc., Malvern, PA: Personal communication.
14. Topol EJ, GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combinaiton reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomized trial. Lancet. 2001; 357: 1905-14.
15. Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). 2004. From http://www.acc.org/clinical/guidelines/stemi/index.pdf and http://www.americanheart.org.
16. Goodman SG, Menon V, Cannon CP et al. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008; 133:708S-75S. [PubMed 18574277]
17. Buller HR, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 2004; 126(Suppl):401S-28S. [IDIS 523841] [PubMed 15383479]
19. The American Heart Association. Guidelines 2005 for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2005; 112(Suppl I):IV1-211.
20. Kearon C, Kahn SR, Agnelli G et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008; 133 (Suppl): 454S-545S. [PubMed 18574272]
HID. Trissel LA. Handbook on injectable drugs. 14th ed; Bethesda, MD: American Society of Health-System Pharmacists; 2007:1462.
Contral may be available in the countries listed below.
Loratadine is reported as an ingredient of Contral in the following countries:
Omeprazole is reported as an ingredient of Contral in the following countries:
International Drug Name Search
Generic Name: calcium and vitamin D combination (KAL see um and VYE ta min D)
Brand Names: Calcarb with D, Calcet, Calcio Del Mar, Calcitrate with D, Calcium 600+D, Caltrate 600 with D, Caltrate 600 with D Plus Soy, Caltrate Colon Health, Citracal + D, Citracal 250 mg + D, Citracal Creamy Bites, Citracal Maximum + D, Citracal Petites, Citrus Calcium with Vitamin D, Dical-D, Os-Cal 250 with D, Os-Cal 500 + D, Os-Cal with D, Oysco 500 with D, Oysco D, Oyst-Cal-D, Oyster Shell Calcium with Vitamin D, Oyster-D, Oystercal-D, Posture-D H/P, Risacal-D
Calcium is a mineral that is found naturally in foods. Calcium is necessary for many normal functions of your body, especially bone formation and maintenance.
Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body.
Calcium and vitamin D combination is used to prevent or to treat a calcium deficiency.
Calcium and vitamin D combination may also be used for other purposes not listed in this medication guide.
Before you take calcium and vitamin D combination, tell your doctor if you have kidney disease, past or present kidney stones, heart disease, circulation problems, a parathyroid disorder, or if you are pregnant or breast-feeding.
Before taking calcium and vitamin D combination, tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
If you have certain conditions, you may need a dose adjustment or special tests to safely use this medication. Before you take calcium and vitamin D combination, tell your doctor if you have:
heart disease;
circulation problems; or
a parathyroid gland disorder.
Take this medication exactly as prescribed by your doctor. Do not take it in larger amounts or for longer than recommended. Follow the directions on your prescription label.
The chewable tablet should be chewed before you swallow it.
Take the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to take the medicine and skip the missed dose. Do not take extra medicine to make up the missed dose.
Overdose symptoms may include irregular heartbeat, stomach pain, nausea, vomiting, dry mouth, a metallic taste in your mouth, confusion, loss of appetite, constipation, weakness, headache, confusion, or fainting.
Less serious side effects may include:
an irregular heartbeat;
nausea, vomiting, or decreased appetite;
dry mouth;
constipation;
weakness;
headache;
a metallic taste;
muscle or bone pain; or
drowsiness.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking calcium and vitamin D combination, tell your doctor if you are taking:
digoxin (Lanoxin, Lanoxicaps);
antacids containing calcium, aluminum, or magnesium;
other calcium supplements;
calcitriol (Rocaltrol) or other vitamin D supplements; or
a tetracycline antibiotic such as demeclocycline (Declomycin), doxycycline (Adoxa, Doryx, Oracea, Vibramycin), minocycline (Dynacin, Minocin, Solodyn, Vectrin), or tetracycline (Brodspec, Panmycin, Sumycin, Tetracap).
This list is not complete and there may be other drugs that can interact with calcium and vitamin D combination. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
Generic Name: brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine (BROM fen IR a meen, KLOR fen IR a meen, METH skoe POL a meen, FEN il EFF rin, SOO doe ee FED drin)
Brand Names: SymPak II
Brompheniramine, chlorpheniramine, and methscopolamine are antihistamines that reduce the effects of the natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.
Phenylephrine and pseudoephedrine are decongestants that shrink blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).
The combination of brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine is used to treat runny or stuffy nose, sneezing, itching, watery eyes, and sinus congestion caused by allergies, the common cold, or the flu.
Brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine may also be used for purposes not listed in this medication guide.
To make sure you can safely take this medication, tell your doctor if you have any of these other conditions:
a blockage in your digestive tract (stomach or intestines), a colostomy or ileostomy;
diabetes;
liver or kidney disease;
epilepsy or other seizure disorder;
cough with mucus, or cough caused by smoking, emphysema, or chronic bronchitis;
enlarged prostate or urination problems;
low blood pressure;
pheochromocytoma (an adrenal gland tumor); or
if you take potassium (Cytra, Epiklor, K-Lyte, K-Phos, Kaon, Klor-Con, Polycitra, Urocit-K).
Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.
Cold medicine is usually taken only for a short time until your symptoms clear up.
Do not take for longer than 7 days in a row. Talk with your doctor if your symptoms do not improve after 7 days of treatment, or if you have a fever with a headache or skin rash.
Since cold medicine is taken when needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
Overdose symptoms may include severe forms of some of the side effects listed in this medication guide.
Avoid taking this medication if you also take diet pills, caffeine pills, or other stimulants (such as ADHD medications). Taking a stimulant together with a decongestant can increase your risk of unpleasant side effects.
fast or uneven heart rate;
pounding heartbeats or fluttering in your chest;
mood changes;
tremor, seizure (convulsions);
double vision;
ongoing diarrhea or vomiting;
easy bruising or bleeding, unusual weakness;
urinating less than usual or not at all;
feeling short of breath; or
dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, uneven heartbeats, seizure).
Less serious side effects may include:
mild headache, dizziness, drowsiness;
dry mouth, nose, or throat;
decreased sense of taste;
nausea, bloating, constipation;
blurred vision;
feeling nervous or restless;
sleep problems (insomnia); or
decreased sweating.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Nasal Congestion:
Brompheniramine/chlorpheniramine/methscopolamine/phenylephrine/pseudoephedrine oral kit:
1 AM tablet orally in the morning and 1 PM tablet orally in the evening.
Usual Pediatric Dose for Nasal Congestion:
Brompheniramine/chlorpheniramine/methscopolamine/phenylephrine/pseudoephedrine oral kit:
6 to 11 years: 1 AM tablet orally in the morning and 1/2 PM tablet orally in the evening.
12 years or older: 1 AM tablet orally in the morning and 1 PM tablet orally in the evening.
Tell your doctor about all other medicines you use, especially:
atropine (Atreza, Sal-Tropine);
benztropine (Cogentin);
topiramate (Topamax);
zonisamide (Zonegran);
anti-nausea medications such as belladonna (Donnatal), dimenhydrinate (Dramamine), droperidol (Inapsine), methscopolamine (Pamine), or scopolamine (Transderm Scop);
bladder or urinary medications such as darifenacin (Enablex), flavoxate (Urispas), oxybutynin (Ditropan, Oxytrol), solifenacin (Vesicare), tolterodine (Detrol), or Urogesic Blue;
bronchodilators such as ipratropium (Atrovent) or tiotropium (Spiriva);
irritable bowel medications such as dicyclomine (Bentyl), hyoscyamine (Hyomax), or propantheline (Pro Banthine); or
ulcer medicine such as glycopyrrolate (Robinul) or mepenzolate (Cantil).
This list is not complete and other drugs may interact with brompheniramine, chlorpheniramine, methscopolamine, phenylephrine, and pseudoephedrine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Flameril may be available in the countries listed below.
Diclofenac diethylamine (a derivative of Diclofenac) is reported as an ingredient of Flameril in the following countries:
Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Flameril in the following countries:
International Drug Name Search
Bruzol may be available in the countries listed below.
Albendazole is reported as an ingredient of Bruzol in the following countries:
International Drug Name Search
In the US, Systen is a member of the drug class estrogens and is used to treat Atrophic Urethritis, Atrophic Vaginitis, Breast Cancer - Palliative, Hypoestrogenism, Oophorectomy, Osteoporosis, Postmenopausal Symptoms, Primary Ovarian Failure and Prostate Cancer.
Estradiol is reported as an ingredient of Systen in the following countries:
Estradiol hemihydrate (a derivative of Estradiol) is reported as an ingredient of Systen in the following countries:
International Drug Name Search
Clonidural may be available in the countries listed below.
Clonidine hydrochloride (a derivative of Clonidine) is reported as an ingredient of Clonidural in the following countries:
International Drug Name Search
See also: Generic Limbitrol
Limbitrol DS is a brand name of amitriptyline/chlordiazepoxide, approved by the FDA in the following formulation(s):
Yes. The following products are equivalent to Limbitrol DS:
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Limbitrol DS. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Limbitrol DS.
P&U Cytarabine may be available in the countries listed below.
Cytarabine is reported as an ingredient of P&U Cytarabine in the following countries:
International Drug Name Search
